Key result
Systemic thrombolysis is linked to ~44% higher odds of favorable 90-day outcomes in ischemic stroke with HF.
Why the study?
There are concerns that systemic thrombolysis might not achieve clinically important outcomes among chronic heart failure patients with acute ischaemic stroke.
Does systemic thrombolysis improve functional outcomes at 90 days in acute ischaemic stroke patients with chronic heart failure?
Cohort (n=5,677)
Yes
Does systemic thrombolysis improve functional outcomes at 90 days in acute ischaemic stroke patients with chronic heart failure?
Systemic thrombolysis improves 90-day functional outcomes in acute ischemic stroke patients regardless of the presence of chronic heart failure, supporting its use in this high-risk population.
May support thrombolysis consideration in stroke with heart failure; extends observational data but leaves open randomized confirmation.
BACKGROUND AND PURPOSE: There are concerns that systemic thrombolysis might not achieve clinically important outcome amongst chronic heart failure (CHF) patients with acute ischaemic stroke. Our aim was to investigate the relevance of CHF on the outcome of acute stroke patients who received thrombolysis. METHODS: A non-randomized cohort analysis was conducted using data obtained from the Virtual International Stroke Trials Archive. The association of outcome amongst CHF patients with thrombolysis treatment was described using the modified Rankin scale (mRS) distribution at day 90, stratified by the presence of atrial fibrillation. Dichotomized outcomes were considered as a secondary end-point. RESULTS: 5677 patients were identified, of whom 2366 (41.7%) received thombolysis. Five hundred and three (8.9%) patients had CHF, of whom 209 (41.6%) received thrombolysis. The presence of CHF was associated with a negative impact on overall stroke outcome [odds ratio (OR) 0.73 (95% confidence interval (CI) 0.62-0.87), P < 0.001]. However, thrombolysis treatment was associated with favourable functional outcome using ordinal mRS, irrespective of CHF status, after adjustment for age and baseline National Institutes of Health Stroke Scale [OR 1.44 (95% CI 1.04-2.01, P = 0.029) for CHF patients versus OR 1.50 (95% CI 1.36-1.66, P < 0.001) for non-CHF patients]. CHF patients had higher mortality at day 90 than non-CHF patients. There was no significant difference for recurrent stroke or symptomatic intracerebral haemorrhage within 7 days of the initial stroke between CHF and thrombolysis groups. CONCLUSIONS: Chronic heart failure was associated with a worse outcome with or without thrombolysis. However, acute stroke patients who received thrombolysis had more favourable outcome regardless of CHF status, compared with their untreated peers. Our findings should reassure clinicians considering systemic thrombolysis treatment in hyperacute ischaemic stroke patients with CHF.
No takes yet. Share an insight, caveat, or question.
Abdul‐Rahim et al. (2014) conducted a cohort in acute ischaemic stroke (n=5,677). Systemic thrombolysis vs. No thrombolysis was evaluated on favourable functional outcome using ordinal modified Rankin scale (mRS) at day 90 (OR 1.44, 95% CI 1.04-2.01, p=0.029). Systemic thrombolysis was associated with favorable functional outcomes at 90 days in acute ischemic stroke patients with chronic heart failure (OR 1.44; 95% CI 1.04-2.01; P=0.029).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: